Gotham Asset Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.75M | Buy |
48,842
+30,028
| +160% | +$1.96M | 0.01% | 1023 |
|
|
2025
Q4 | $1.51M | Sell |
18,814
-4,114
| -18% | -$276K | 0.01% | 1132 |
|
|
2025
Q3 | $1.12M | Buy |
22,928
+91
| +0.4% | +$5.63K | ﹤0.01% | 1162 |
|
|
2025
Q2 | $1.7M | Buy |
22,837
+18,158
| +388% | +$1.2M | 0.01% | 975 |
|
|
2025
Q1 | $297K | Sell |
4,679
-235
| -5% | -$16K | ﹤0.01% | 1366 |
|
|
2024
Q4 | $384K | Hold |
4,914
| – | – | ﹤0.01% | 1200 |
|
|
2024
Q3 | $395K | Sell |
4,914
-4
| -0.1% | -$323 | ﹤0.01% | 1160 |
|
|
2024
Q2 | $407K | Sell |
4,918
-3,694
| -43% | -$325K | 0.01% | 1142 |
|
|
2024
Q1 | $735K | Sell |
8,612
-15,318
| -64% | -$1.2M | 0.01% | 933 |
|
|
2023
Q4 | $2.05M | Sell |
23,930
-2,588
| -10% | -$224K | 0.04% | 601 |
|
|
2023
Q3 | $2.38M | Buy |
26,518
+5,352
| +25% | +$478K | 0.05% | 503 |
|
|
2023
Q2 | $1.8M | Buy |
21,166
+13,668
| +182% | +$1.16M | 0.04% | 578 |
|
|
2023
Q1 | $620K | Sell |
7,498
-4,187
| -36% | -$339K | 0.02% | 887 |
|
|
2022
Q4 | $919K | Buy |
11,685
+6,542
| +127% | +$526K | 0.03% | 714 |
|
|
2022
Q3 | $381K | Sell |
5,143
-1
| -0% | -$72 | 0.01% | 913 |
|
|
2022
Q2 | $335K | Buy |
+5,144
| New | +$304K | 0.01% | 895 |
|
|
2022
Q1 | – | Sell |
-6,453
| Closed | -$342K | – | 1178 |
|
|
2021
Q4 | $342K | Sell |
6,453
-341
| -5% | -$20.8K | 0.01% | 911 |
|
|
2021
Q3 | $480K | Buy |
+6,794
| New | +$429K | 0.02% | 678 |
|
|
2020
Q3 | – | Sell |
-6,684
| Closed | -$599K | – | 1076 |
|
|
2020
Q2 | $599K | Sell |
6,684
-14,582
| -69% | -$1.47M | 0.02% | 702 |
|
|
2020
Q1 | $2.12M | Buy |
21,266
+16,377
| +335% | +$1.78M | 0.06% | 398 |
|
|
2019
Q4 | $562K | Buy |
+4,889
| New | +$592K | 0.01% | 776 |
|
|
2019
Q2 | – | Sell |
-18,653
| Closed | -$1.63M | – | 1198 |
|
|
2019
Q1 | $1.63M | Sell |
18,653
-18,111
| -49% | -$1.65M | 0.02% | 534 |
|
|
2018
Q4 | $3.68M | Sell |
36,764
-8,903
| -19% | -$935K | 0.06% | 387 |
|
|
2018
Q3 | $5.23M | Sell |
45,667
-9,805
| -18% | -$1.02M | 0.07% | 337 |
|
|
2018
Q2 | $4.97M | Sell |
55,472
-98,869
| -64% | -$8.35M | 0.07% | 343 |
|
|
2018
Q1 | $11.3M | Buy |
154,341
+129,218
| +514% | +$8.87M | 0.16% | 207 |
|
|
2017
Q4 | $1.46M | Sell |
25,123
-30,438
| -55% | -$1.6M | 0.02% | 535 |
|
|
2017
Q3 | $2.49M | Buy |
55,561
+18,088
| +48% | +$752K | 0.04% | 479 |
|
|
2017
Q2 | $1.48M | Buy |
37,473
+21,665
| +137% | +$890K | 0.02% | 577 |
|
|
2017
Q1 | $641K | Buy |
+15,808
| New | +$617K | 0.01% | 731 |
|
|
2016
Q3 | – | Sell |
-39,575
| Closed | -$1.15M | – | 968 |
|
|
2016
Q2 | $1.15M | Buy |
+39,575
| New | +$1.2M | 0.01% | 612 |
|
|
2015
Q3 | – | Sell |
-35,271
| Closed | -$1.46M | – | 965 |
|
|
2015
Q2 | $1.46M | Buy |
35,271
+27,761
| +370% | +$1.17M | 0.01% | 583 |
|
|
2015
Q1 | $337K | Buy |
+7,510
| New | +$314K | ﹤0.01% | 771 |
|
|
2014
Q4 | – | Sell |
-29,531
| Closed | -$1.03M | – | 988 |
|
|
2014
Q3 | $1.03M | Sell |
29,531
-9,059
| -23% | -$323K | 0.01% | 621 |
|
|
2014
Q2 | $1.36M | Sell |
38,590
-4,219
| -10% | -$141K | 0.02% | 592 |
|
|
2014
Q1 | $1.4M | Buy |
+42,809
| New | +$1.64M | 0.02% | 592 |
|
Other funds holding HAE
VPM
VCM
RRAM
Gotham Asset Management's HAE Position: Q1 2026 in Review
Gotham Asset Management increased its Haemonetics (HAE) stake by 160% in Q1 2026, buying an estimated $1.96M and bringing the position to 48,842 shares worth $2.75M. The position accounts for 0.01% of the portfolio, ranked #1023.
Gotham Asset Management first reported a position in HAE in Q1 2014 and has held it in 36 quarters since. The position peaked at $11.3M in Q1 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Gotham Asset Management held 48,842 shares of Haemonetics worth $2.75M as of Q1 2026.
- Gotham Asset Management bought 30,028 Haemonetics shares in Q1 2026, an estimated $1.96M.
- Haemonetics made up 0.01% of Gotham Asset Management's portfolio in Q1 2026, its #1023 holding.
- Gotham Asset Management first reported a position in Haemonetics in Q1 2014 and has held it in 36 quarters since.
- Gotham Asset Management's Haemonetics position peaked at $11.3M in Q1 2018.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.